{"id":49700,"date":"2022-10-17T17:01:49","date_gmt":"2022-10-17T15:01:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/orange-county-research-institute-enrolling-patients-in-anaheim-for-clinical-trial-of-promising-new-investigational-treatment-for-alzheimers-disease\/"},"modified":"2022-10-17T17:01:49","modified_gmt":"2022-10-17T15:01:49","slug":"orange-county-research-institute-enrolling-patients-in-anaheim-for-clinical-trial-of-promising-new-investigational-treatment-for-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/orange-county-research-institute-enrolling-patients-in-anaheim-for-clinical-trial-of-promising-new-investigational-treatment-for-alzheimers-disease\/","title":{"rendered":"Orange County Research Institute Enrolling Patients in Anaheim for Clinical Trial of Promising New Investigational Treatment for Alzheimer\u2019s Disease"},"content":{"rendered":"
\n

\nIndividuals with memory problems encouraged to learn more about study<\/i>\n<\/p>\n

ANAHEIM, Calif.–(BUSINESS WIRE)–Orange County Research Institute (OCRI) is initiating a clinical trial for a promising new investigational treatment for Alzheimer\u2019s disease (AD) in Anaheim.\n<\/p>\n

<\/a><\/p>\n

\nThe Phase I study will determine the safety and tolerability of a single intravenous (IV) dose and multiple IV doses of ACU193. We are asking individuals who have memory problems to consider participating in the trial to assist in evaluating this medication for the treatment of Alzheimer\u2019s disease. There is no cost to participate. Acumen Pharmaceuticals Inc.<\/a>, a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for AD, is sponsoring the clinical trial.\n<\/p>\n

\nACU193 targets amyloid-beta oligomers and is a different approach to treating Alzheimer\u2019s disease than currently approved medications. ACU193 is designed to locate and bind to amyloid-beta oligomers \u2013 proteins that build up in the brain in people with Alzheimer\u2019s disease. These proteins are thought to be involved in Alzheimer\u2019s disease symptoms and progression.\n<\/p>\n

\nThe trial site, located at 1801 W. Romneya Dr., Suite 409, Anaheim, CA 92801, is led by principal investigator Dr. Steve Sitar at OCRI. <\/strong>Patients who believe they qualify for the study are asked to call Cassandra at (714) 635-7100 or email cvaldez@ocri.us<\/a> to learn more.\n<\/p>\n

\n\u201cWe\u2019re excited to open this trial in Anaheim to study ACU193 for the treatment of Alzheimer\u2019s disease,\u201d Dr. Sitar said. \u201cIf you or a loved one is experiencing memory problems, contact us to find out more about the study. More than 6 million Americans are living with Alzheimer\u2019s disease. New, safe and effective treatments are needed more than ever. Participating in clinical trials is one way members of our community can help make a difference.\u201d\n<\/p>\n

\nKey Eligibility Criteria:<\/b>\n<\/p>\n